Published in AIDS Weekly, July 21st, 2003
Patients in this study treated with IMMUNITIN (HE2000), the company's lead investigational compound for infectious disease, experienced a statistically significant reduction in the total number of all opportunistic infections (OIs) over the 13-month study period when compared to patients receiving placebo.
There were 25 evaluable patients in the study who were dosed once a day with either IMMUNITIN or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.